Adjuvant interferon therapy in high-risk melanoma: For which patients? [Adjuvante Interferontherapie beim Hochrisikomelanom : Welche Patienten kommen in Frage?]

被引：0
|
作者：
Hauschild A. [1 ,2 ]
Kähler C. [1 ]
机构：
[1] Klinik für Dermatologie, Venerologie und Allergologie, Universitätsklinikum Schleswig-Holstein, Kiel
[2] Klinik für Dermatologie, Venerologie und Allergologie, Universitätsklinikum Schleswig-Holstein, Campus Kiel, 24105 Kiel
来源：
best practice onkologie | 2007年 / 2卷 / 2期
关键词：
D O I：
10.1007/s11654-007-0014-7
中图分类号：
学科分类号：
摘要：
[No abstract available]
引用
收藏
页码：4 / 13
页数：9
相关论文
共 50 条
  • [31] Adjuvant therapy with high-dose interferon α2b in patients with high-risk stage IIB/III melanoma
    John M Kirkwood
    Ahmad A Tarhini
    Stergios J Moschos
    Monica C Panelli
    Nature Clinical Practice Oncology, 2008, 5 : 2 - 3
  • [32] Adjuvant interferon alfa-2b for high-risk melanoma
    Retsas, S
    JOURNAL OF CLINICAL ONCOLOGY, 1996, 14 (06) : 1968 - 1968
  • [33] Malignant melanoma - Interferon alpha: an important option in the therapy of high-risk patients
    不详
    HAUTARZT, 2005, 56 (12): : 1190 - 1190
  • [34] Adjuvant high-dose interferon alfa-2b in patients with high-risk melanoma
    Jonasch, E
    Kumar, UN
    Linette, GP
    Hodi, FS
    Soiffer, RJ
    Ryan, BF
    Sober, AJ
    Mihm, MC
    Tsao, H
    Langley, RG
    Cosimi, BA
    Gadd, MA
    Tanabe, KK
    Souba, W
    Haynes, HA
    Barnhill, R
    Osteen, R
    Haluska, FG
    CANCER JOURNAL, 2000, 6 (03): : 139 - 145
  • [35] Cutaneous melanoma: interferon alpha adjuvant therapy for patients at high risk for recurrent disease
    Lens, Marko
    DERMATOLOGIC THERAPY, 2006, 19 (01) : 9 - 18
  • [36] Adjuvant Interferon Therapy for Patients at High Risk for Recurrent Melanoma: An Updated Systematic Review
    Larkin, J. M. G.
    Fisher, R. A.
    Gore, M. E.
    CLINICAL ONCOLOGY, 2012, 24 (06) : 410 - 412
  • [37] The adjuvant treatment revolution for high-risk melanoma patients
    Spagnolo, Francesco
    Boutros, Andrea
    Tanda, Enrica
    Queirolo, Paola
    SEMINARS IN CANCER BIOLOGY, 2019, 59 : 283 - 289
  • [38] Association of HLA polymorphism and outcome in high-risk Greek melanoma patients receiving adjuvant interferon
    Spyropoulou-Vachou, Maria
    Gogas, Helen
    Dafni, Urania
    Tsoutsos, Dimosthenis
    Vrani, Vasiliki
    Dinou, Melina
    Stavropoulos-Giokas, Catherine
    TISSUE ANTIGENS, 2009, 73 (05): : 519 - 519
  • [39] Evaluation of CTLA-4 polymorphisms in high-risk melanoma patients receiving adjuvant interferon
    Gogas, H.
    Metaxas, Y.
    Dafni, U.
    Polyzos, A.
    Fountzilas, G.
    Pectasides, E.
    Skarlos, D.
    Tsoutsos, D.
    Panagiotou, P.
    Spyropoulou-Vlachou, M.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [40] Adjuvant therapy of high-risk melanoma: The role of high-dose interferon alpha-2b
    Kirkwood, JM
    Strawderman, MH
    Ernstoff, MS
    Smith, T
    Borden, E
    Blum, R
    ADJUVANT THERAPY OF CANCER VIII, 1997, 8 : 251 - 257
12345